Turkish Society of Cardiology Young Cardiologists Bulletin / "TSCYOUNG" Eylül 2021 (2)

[Türkçe]

Turkish Society of Cardiology Young Cardiologists Bulletin Year: 4 Number: 2 / 2021

Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin

Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan

Coordinator for the
Board of Directors
Dr. Can Yücel Karabay

Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı

Bulletin Editors
Muzaffer Değertekin
Bülent Mutlu
Süleyman Çağan Efe
Alper Karakuş
Elif Hande Özcan Çetin

Contributors
Duygu İnan
Dursun Akaslan
Süleyman Çağan Efe
Alper Karakuş
Göksel Çinier
Elif Hande Özcan Çetin
Oğuzhan Birdal
Serhat Sığırcı
Ümit Yaşar Sinan
İbrahim Rencüzoğulları
Sedat Kalkan
Gökay Taylan
Murat Çap
Kerim Esenboğa
Mustafa Yılmaztepe
Emrah Erdoğan

Turkish Society of Cardiology Young Cardiologists Bulletin / "TSCYOUNG" Eylül 2021 (2)

Turkish Society of Cardiology Young Bulletin ESC 2021 Hot Line Trials 4:2

Dear Colleagues,
As the Young Cardiologists Group of the Turkish Society of Cardiology, we are pleased to present the second issue of the TSC Bulletin for 2021, which includes the latest clinical trials in the field of cardiology. The studies in the bulletin were selected from the Hot Line studies published at the ESC 2021 Congress.
The studies have been summarized as briefly as possible to provide an overview, provide both informative and useful references for daily practice.
Thanks to our colleagues who contributed to bulletin. We hope it will be a useful resource for our colleagues.

Issue Summary


	Influenza Vaccination after Myocardial Infarction: Randomized Trial- IAMI Dr. Gökay Taylan
	During influenza epidemics, deaths from cardiovascular diseasIe occur at a higher rate comparing with non-epidemic periods. Observational and small randomized studies suggest that the influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease.


	Name of the Study: Amplatzer^™ Amulet^™ Left Atrial Appendage Occluder Versus Watchman^™ Device For Stroke Prophylaxis (Amulet IDE): A Randomized Controlled Trial Dr. Mustafa Yılmaztepe
	Patients with atrial fibrillation are at increased risk of ischemic stroke due to left atrial blood stasis that cause left atrial appendage thrombus formation.


	AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrowQRS: the APAF-CRT mortality trial Dr. Göksel Cinier
	Heart failure (AF) and concomitant atrial fibrillation (AF) poses a distinct challenge for clinicians. Although recent trials demonstrated mortality benefit with AF ablation in this subgroup of patients, best treatment option for those who could not undergo ablation is not known.


	DECAAF II: efficacy of DE-MRI-guided fibrosis ablation vs. conventional catheter ablation of persistent atrial fibrillation Dr. Elif Hande Özcan Çetin
	The DECAAF study, published in 2014, showed that atrial fibrotic tissue detected by delayed contrast magnetic resonance imaging (MRI) was associated with the likelihood of recurrent arrhythmias in AF patients undergoing catheter ablation.


	Empagliflozin in Heart Failure with a Preserved Ejection Fraction- EMPEROR- Preserved Dr. Duygu İnan
	Sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the risk of cardiovacular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their certain effects in patients with heart failure and a preserved ejection fraction are unknown


	Edoxaban vs. Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation–Atrial Fibrillation - ENVISAGE-TAVI AF Dr. Alper Karakuş
	The GALILEO trial demonstrated more harm than benefit with low-dose rivaroxaban compared to antiplatelet therapy in patients who underwent transcatheter aortic valve replacement (TAVR) and did not have atrial fibrillation (AF).


	STEP Study: intensive vs. standard blood pressure control among older hypertensive patients Dr. Kerim Esenboğa
	In elderly persons, achieving the appropriate systolic blood pressure (SBP) treatment target is challenging. Furthermore, blood pressure lowering trials in older persons with hypertension have had inconsistent findings, and different target values are recommended by guidelines.


	Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy Dr. Ümit Yaşar Sinan
	Severely stenosed carotid arteries predispose to stroke, and either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce the long-term risk of stroke.


	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Dr. Duygu İnan
	Pulmonary congestion is a major cause of reduced functional capacity, poor quality of life, recurrent heart failure hospitalizations and increased mortality in patients with heart failure.


	Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation (TOMAHAWK) Dr. Oğuzhan Birdal
	Patients who develop out-of-hospital cardiac arrest (OHCA) have a poor prognosis and have a mortality rate of up to 65%, even if these patients are successfully resuscitated and admission to the hospital.


	Detection of Atrial Fibrillation with Implantable Loop Recorder in Prevention of Stroke (The LOOP Study): A Randomized Controlled Study Dr. İbrahim Rencüzoğulları
	The risk of stroke is five times higher in people with atrial fibrillation (AF) than in those without. In addition, strokes secondary to AF are associated with worse outcomes than strokes that develop in the absence of AF.


	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk MASTER DAPT Dr. Süleyman Çağan Efe
	The duration of dual antiplatelet therapy after acute coronary syndromes is getting shorter with the development of new generation stent technologies. after randomized controlled studies, it is included in the 2020 NSTMI ESC guidelines in patients with high and very high bleeding risk 3 months and 1 month dual treatment with a recommendation level of 2a .


	Cardiovascular Safety of Degarelix versus Leuprolide in Patients with Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Dr. Murat ÇAP
	Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of non-cancer death in patients with prostate cancer. Androjen deprivation therapy (ADT) by orchiectomy or medical therapy has been a cornerstone of treatment for patients with advanced prostate cancer for decades.


	Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain? – RIPCORD 2 Dr. Serhat Sığırcı
	The traditional approach to angina is based on either assessment of the coronary anatomy by angiography or noninvasive testing for reversible ischemia.


	Implantable cardiac monitors in high-risk post-infarction patients with cardiac autonomic dysfunction and moderately reduced left ventricular ejection fraction: SMART-MI DZHK9 Dr. Dursun Akaslan
	Intracardiac defibrillator (ICD) therapy is recommended for prevention of sudden cardiac death in patients with severely reduced left ventricular ejection fraction (LVEF; 35% or less) after myocardial infarction (MI).


	Effect of Salt Substitution on Cardiovascular Events and Death Dr. Sedat Kalkan
	It is known that the use of salt with low sodium content instead of normal salt use reduces blood pressure. In this study, the cardiovascular safety and efficacy results of salt replacement were evaluated.


	One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome: STOPDAPT-2 ACS Trial Dr. Emrah Erdoğan
	The current European guidelines recommend dual antiplatelet therapy (DAPT) for at least 12 months after percutaneous coronary intervention(PCI) in acute coronary syndrome(ACS).


	Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease - FIGARO-DKD Dr. Alper Karakuş
	In the FIDELIO-DKD study, finerenone was shown to reduce cardiovascular (CV) adverse events and mortality in type 2 diabetes (T2DM) patients with severe chronic kidney disease (CKD).